Patent Application
20240131167
Provided herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation.
The disclosure also provides pharmaceutically acceptable compositions comprising compounds and methods for the treatment of EGFR mutant-related cancers.
Proteolysis targeting chimera (PROTAC) consists of two covalently linked protein-binding molecules: one capable of engaging an E3 ubiquitin ligase, and another that binds to the protein of interest (POI) a target meant for degradation (Sakamoto K M et al., Proc. Natl. Acad Sci. 2001, 98: 8554-9; Sakamoto K. M. et al., Methods Enzymol. 2005, 399:833-847.). Rather than inhibiting the target protein's enzymatic activity, recruitment of the E3 ligase to the specific unwanted proteins results in ubiquitination and subsequent degradation of the target protein by the proteasome. The whole process of ubiquitination and proteasomal degradation is known as the ubiquitin-proteasome pathway (UPP) (Ardley H. et al., Essays Biochem. 2005, 41, 15-30; Komander D. et al., Biochem. 2012, 81, 203-229; Grice G. L. et al., Cell Rep. 2015, 12, 545-553; Swatek K. N. et al., Cell Res. 2016, 26, 399-422). Proteasomes are protein complexes which degrade unneeded, misfolded or abnormal proteins into small peptides to maintain health and productivity of the cells. Ubiquitin ligases, also called an E3 ubiquitin ligase, directly catalyze the transfer of ubiquitin from the E2 to the target protein for degradation. Although the human genome encodes over 600 putative E3 ligases, only a limited number of E3 ubiquitin ligases have been widely applied by small molecule PROTAC technology: cereblon (CRBN), Von Hippel-Lindau (VHL), mouse double minute 2 homologue (MDM2) and cellular inhibitor of apoptosis protein (cIAP) (Philipp O. et al., Chem. Biol. 2017, 12, 2570-2578), recombinant Human Ring Finger Protein 114 (RNF114) (Spradlin, J. N. et al. Nat. Chem. Biol. 2019, 15, 747-755) and DDB1 And CUL4 Associated Factor 16 (DCAF16) (Zhang, X. et al. Nat. Chem. Biol. 2019, 15, 737-746). For example, cereblon (CRBN) forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and Cullin-4A (CUL4A) to ubiquitinate a number of other proteins followed by the degradation via proteasomes. (Yi-An Chen, et al., Scientific Reports 2015, 5, 1-13). Immunomodulatory drugs (IMiDs), including thalidomide, lenalidomide, and pomalidomide, function as monovalent promoters of PPIs by binding to the cereblon (CRBN) subunit of the CRL4ACRBN E3 ligase complex and recruiting neosubstrate proteins. (Matyskiela, M. E. et al., Nat Chem Biol 2018, 14, 981-987.) As a consequence, the ability of thalidomide, and its derivatives, to recruit CRBN has been widely applied in proteolysis-targeting chimeras (PROTACs) related studies (Christopher T. et al. ACS Chem. Biol. 2019, 14, 342-347; Honorine L. et al. ACS Cent. Sci. 2016, 2, 927-934). PROTACs have great potential to eliminate protein targets that are “undruggable” by traditional inhibitors or are non-enzymatic proteins. (Chu T T. et al., Cell Chem Biol. 2016; 23:453-461. Qin C. et al., J Med Chem 2018; 61: 6685-6704. Winter G E. et al., Science 2015; 348:1376-1381.) In the recent years, PROTACs as useful modulators promote the selective degradation of a wide range of target proteins have been reported in antitumor studies. (Lu J. et al., Chem Biol. 2015; 22(6):755-763; Ottis P. et al., Chem Biol. 2017: 12(4):892-898. Crews C. M. et al., J Med Chem. 2018; 61(2):403-404; Neklesa T. K. et al., Pharmacol Ther. 2017, 174:138-144. Cermakova K. et al., Molecules, 2018.23(8). An S. et al., EBioMedicine, 2018. Lebraud H. et al., Essays Biochem. 2017; 61(5): 517-527. Sun Y. H. et al., Cell Res. 2018; 28:779-81; Toure M. et al., Angew Chem Int Ed Engl. 2016:55(6):1966-1973; Yonghui Sun et al., Leukemia, volume 33, pages 2105-2110(2019); Shaodong Liu et al., Medicinal Chemistry Research, volume 29, pages 802-808(2020); and has been disclosed or discussed in patent publications, e.g., US20160045607, US20170008904, US20180050021, US20180072711, WO2002020740, WO2014108452, WO2016146985, WO2016149668, WO2016197032, WO2016197114, WO2017011590, WO2017030814, WO2017079267, WO2017182418, WO2017197036, WO2017197046, WO2017197051, WO2017197056, WO2017201449, and WO2018071606.
Epidermal growth factor receptor (EGFR) that belongs to the ErbB family is a transmembrane receptor tyrosine kinase (RTK), which plays a fundamentally key role in cell proliferation, differentiation, and motility (Y. Yarden, et al., Nat. Rev. Mol. Cell Biol. 2001; 2:127-137.). Homo- or heterodimerization of EGFR and other ErbB family members activates cytoplasmic tyrosine kinase domains to initiate intracellular signaling. Overexpression or activating mutations of EGFR are associated the development of many types of cancers, such as pancreatic cancer, breast cancer, glioblastoma multiforme, head and neck cancer, and non-small cell lung cancer (Yewale C., et al. Biomaterials. 2013, 34 (34): 8690-8707.). The activating mutations in the EGFR tyrosine kinase domain (L858R mutation and exon-19 deletion) have been identified as oncogenic drivers for NSCLC (Konduri, K., et al. Cancer Discovery 2016, 6 (6), 601-611.). The first-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib have approved for NSCLC patients with EGFR activation mutations (M. Maemondo. N. Engl. J. Med 362 (2010) 2380-2388.). Although most patients with EGFR mutant NSCLC respond to these therapies, patients typically develop resistance after an average of one year on treatment. There are several mechanisms of acquired resistance to gefitinib and erlotinib, including a secondary threonine 790 to methionine 790 mutation (T790M), is also called “gatekeeper” T790M mutation (Xu Y., et al. Cancer Biol Ther. 2010, 9 (8): 572-582.). Therefore, the second-generation EGFR-TKIs afatinib and the third-generation EGFR-TKIs osimertinib (AZD9291) were developed as irreversible EGFR inhibitors that bind to Cys797 for the treatment of patients with T790M mutation. In particular, osimertinib that largely spares WvT EGFR has achieved greater clinical response rate in NSCLC patients with EGFR T790M. However, several recent studies have reported a tertiary Cys797 to Ser797 (C797S) point mutation with osimertinib clinical therapy (Thress K S. et al. Nat. Med 2015, 21 (6): 560-562.). There is a need for drugs which can overcome EGFR (C797S) resistance obstacle in non-small cell lung cancer (NSCLC). EGFR-Targeting PROTACs serve as a potential strategy to overcome drug resistance mediated by these mutants, which has been disclosed or discussed in patent publications, e.g. WO2018119441, WO2019149922, WO2019183523, WO2019121562, US20190106417 and WO202173498.
Although, a number of EGFR-targeting PROTACs which were designed to degrade EGFR mutant proteins have been published (Zhang X., et al. Eur. J. Med Chem. 2020, 192, 112199. Zhang H. et al. Eur. J. Med Chem. 2020, 189, 112061. Lu X, Med Res. Rev. 2018, 38(5):1550-1581. He K., et al. Bioorg. Med Chem. Lett. 2020, 15, 127167.). Most of the published molecules are based on first, second, and third generation of EGFR inhibitors. However, there were no data which showed those EGFR-Targeting PROTACs degrading all the main EGFR mutations, Such as Del19, L858R, Del19/T790M, L858R, T790M, Del19/T790M/C797S, L858R/T790M/C797S.
The present application provides novel bifunctional compounds and compositions for the treatment of serious diseases.
Aspect 1. A compound of Formula (X):
or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a deuterated analog thereof, wherein:
moiety, and **L3 refers to the position attached to the
moiety.
Aspect 2. The compound of Aspect 1, wherein Cy1 is a 4-, 5-, 6- or 7-membered saturated or partially unsaturated ring including P═O, said ring comprising 0 or 1 additional heteroatom independently selected from nitrogen, oxygen or sulfur in addition to P═O; said ring is optionally substituted with at least one substituent R1c;
Aspect 3. The compound of any one of Aspects 1-2, wherein the
moiety is selected from
Aspect 4. The compound of any one of Aspects 1-3, wherein the
moiety is selected from
Aspect 5. The compound of any one of Aspects 1-4, wherein R2 and R3 are each independently selected from hydrogen, —F, —Cl, —Br, —I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, C6-C12aryl, 5- to 12-membered heteroaryl, —CN, —OR2a, —SO2R2a, —SO2NR2aR2b, —COR2a—, —CO2R2a, —CONR2aR2b, —NR2aR2b, —NR2aCOR2b, —NR2aCO2R2b, or —NR2aSO2R2b, wherein each of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, C6-C12aryl or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent R2d.
Aspect 6. The compound of any one of Aspects 1-5, wherein R2 and R3 are each independently selected from hydrogen, halogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl or octyl, preferable selected from —H, —F, —Cl, —Br, —I, —CH3, —CH2CH3, —CH2CH2CH3, —CH(CH3)2, —CH2CH2CH2CH3, —CH(CH3)CH2CH3, —CH2CH(CH3)2, or —C(CH3)3.
Aspect 7. The compound of any one of Aspects 1-4, wherein Z5 is —CR2 and Z6 is —CR3, wherein R2 and R3 together with the carbon atoms to which they are attached, form a 5 or 6 membered unsaturated (preferred aromatic) ring, said ring comprising 0, 1 or 2 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent R2e;
Aspect 8. The compound of any one of Aspects 1-7, wherein the
moiety is
wherein Cy2 is a 5-6 membered unsaturated (preferred aromatic) or saturated ring, said ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;
Aspect 9. The compound any of Aspects 1-8, wherein R2e at each of its occurrences, is independently hydrogen, —F, —Cl, —Br, —I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxyl, ethoxyl, propoxyl, butoxyl, pentoxyl, hexoxyl, heptyloxyl, octyloxyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or oxo, wherein each of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxyl, ethoxyl, propoxyl, butoxyl, pentoxyl, hexoxyl, heptyloxyl, octyloxyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl is optionally substituted with at least one substituent R2d;
Aspect 10. The compound any one of Aspects 1-9, wherein R2e at each of its occurrences, is independently hydrogen, —F, —Cl, —Br, —I, —CH3, —CH2CH3, —CH2CH2CH3, —CH(CH3)2, —CH2CH2CH2CH3, —CH(CH3)CH2CH3, —CH2CH(CH3)2, —C(CH3)3,
Aspect 11. The compound of one of Aspects 1-10, wherein the
moiety is
Aspect 12. The compound of any one of Aspects 1-11, wherein R9, R10, R11 and R12 are each independently selected from hydrogen, —F, —Cl, —Br, —I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxyl, ethoxyl, propoxyl, butoxyl, pentoxyl, hexoxyl, heptyloxyl, octyloxyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, —NH2 or oxo, wherein each of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxyl, ethoxyl, propoxyl, butoxyl, pentoxyl, hexoxyl, heptyloxyl, octyloxyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl is optionally substituted with at least one substituent R9c; or
Aspect 13. The compound of any one of Aspects 1-12, wherein R9, R10, R11 and R12 are each independently selected from hydrogen, F, Cl, Br, —NH2, —CH3, —C2H5, —C3H7, —CH2F, —CHF2, —CF3, —C4H9, —C5H11, —OCH3, —OC2H5, —OC3H7, —OC4H9, —OC5H11, —CN, cyclopropyl or oxo; or
Aspect 14. The compound of any one of Aspects 1-13, wherein R4 is selected from —H, —F, —Cl, —Br, —I, —CH3, —C2H5, —C3H7, —C4H9, —C5H11, —OCH3, —OC2H5, —OC3H7, —OC4H9, —OC5H11, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl or —CN, wherein each of —CH3, —C2H5, —C3H7, —C4H9, —C5H11, —OCH3, —OC2H5, —OC3H7, —OC4H9, —OC5H11, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or phenyl is optionally substituted with —F, —Cl, —Br, —I, —C1-8alkyl, —C2-8alkenyl, —C2-8alkynyl, —C3-C8cycloalkyl, 3- to 8-membered heterocyclyl, C6-C12aryl, 5- to 12-membered heteroaryl, oxo, —CN, —OR4c, —SO2R4c, —SO2NR4cR4d, —COR4c, —CO2R4c, —CONR4cR4d, —NR4cR4d, —NR4cCOR4d, —NR4cCO2R4d, or —NR4cSO2R4d;
Aspect 15. The compound of any one of Aspects 1-14, wherein R4 is Selected from —F, —Cl, —Br, —I, —CH3, —CF3, —CH2F, or —CHF2.
Aspect 16. The compound of any one of Aspects 1-15, wherein L1 is selected from a single bond, —O—, —SO2—, —C(O)—, —NRL1a—, —C1-8alkylene, —C3-C8cycloalkylene-, *L1—O—C1-8alkylene-**L1, L1C1-8alkylene-O—**L1, *L1—SO2—C1-8alkylene-**L1, *L1—C1-8alkylene-SO2—**L1, *L1—CO—C1-8alkylene-**L1, *L1—C1-8alklylene-CO—**L1, *L1—NRL1a—C1-8alkylene-**L1, *L1—C1-8alkylene-NRL1a—**L1, *L1—NRL1aC(O)—**L1, *L1—C(O)NRL1a—**L1, —C1-8alkylene-, —C2-8alkenylene-, —C2-8alkynylene-, —[O(CRL1aRL1b)m4]m5—,
Aspect 17. The compound of any one of Aspects 1-16, wherein L1 is selected from a single bond, —C1-8alkylene- (preferably —CH2—, —C2H4—, —C3H6—), —CO—, —O—, —N(CH3)—, —NH—,
Aspect 18. The compound of any one of Aspects 1-17, wherein X1 and X2 are each independently selected from —CRa or N;
Aspect 19. The compound of any one of Aspects 1-18, wherein m1 is 1; preferably,
moiety is
wherein *X refers to the position attached to
moiety, and **X refers to the position attached to the
moiety.
Aspect 20. The compound of any one of Aspects 1-19, wherein m1 is 0.
Aspect 21. The compound of any one of Aspects 1-20, wherein
moiety is
Aspect 22. The compound of any one of Aspects 1-21, wherein m2 is selected from 0, 1, 2, 3, 4 or 5.
Aspect 23. The compound of any one of Aspects 1-24, wherein L2 is selected from a single bond, —O—, —SO2—, —CO—, —NRL2a—, —C1-8alkylene, —C3-C8cycloalkylene-, *L2—O—C1-8alkylene-**L2, L2C1-8alkylene-O—**L2, *L2—SO2—C1-8alkylene-**L2, *L2—C1-8alkylene-SO2—**L2, *L2—CO—C1-8alkylene-**L2, *L2—C1-8alklylene-CO—**L2, *L2—NRL2a—C1-8alkylene-**L2, *L2—C1-8alkylene-NRL2a—**L2, *L2—NRL2aC(O)—**L2, *L2—C(O)NRL2a—**L2, —C1-8alkylene-, —C2-8alkenylene-, —C2-8alkynylene-, —[O(CRL2aRL2b)m4]m5—,
Aspect 24. The compound of any one of Aspects 1-23, wherein L2 is selected from a single bond, —C1-8alkylene- (preferably —CH2—, —C2H4—, —C3H6—), —CO—, —O—, —N(CH3)—, —NH—,
Aspect 25. The compound of any one of Aspects 1-24, wherein m3 is 0, 1, 2, 3, 4, 5 or 6.
Aspect 26. The compound of any one of Aspects 1-25, wherein L3 is selected from a single bond, —O—, —SO2—, —CO—, —NRL3a—, —C1-8alkylene, —C3-C8cycloalkylene-, *L3—O—C1-8alkylene-**L3, L3C1-8alkylene-O—**L3, *L3—SO2—C1-8alkylene-**L3, *L3—C1-8alkylene-SO2—**L3, *L3—CO—C1-8alkylene-**L3, *L3—C1-8alklylene-CO—**L3, *L3—NRL3a—C1-8alkylene-**L3, *L3—C1-8alkylene-NRL3a—**L3, *L3—NRL3aC(O)—**L3, *L3—C(O)NRL3a—**L3, —C1-8alkylene-, —C2-8alkenylene-, —C2-8alkynylene-, —[O(CRL3aRL3b)m4]m5—,
Aspect 27. The compound of any one of Aspects 1-26, wherein L3 is selected from single bond, —C1-8alkylene- (preferably —CH2—, —C2H4—, —C3H6—), —CO—, —O—, —N(CH3)—, —NH—,
Aspect 28. The compound of any one of Aspects 1-27, wherein
is selected from —CH2CH2—,
wherein * refers to the position attached to
moiety, and ** refers to the position attached to the
moiety.
Aspect 29. The compound of any one of Aspects 1-28, wherein
is selected from
Aspect 30. The compound of any one of Aspects 1-29, wherein
is
Aspect 31. The compound of any one of Aspects 1-30, wherein
is selected from
Aspect 32. The compound of any one of Aspects 1-31, wherein Z1, Z2, Z3 and Z4 are each independently —CRz;
Aspect 33. The compound of any one of Aspects 1-32, wherein Rz is independently selected from H, —CH3, —C2H5, F, —CH2F, —CHF2, —CF3, —OCH3, —OC2H5, —C3H7, —OCH2F, —OCHF2, —OCH2CF3, —OCF3, —SCF3, —CF3, cyclopropyl or —CH(OH)CH3.
Aspect 34. The compound of any one of Aspects 1-33, wherein the deuterium substitution is on degron, preferable, deuterium substitution is on X8.
Aspect 35. The compound of any one of Aspects 1-34, wherein the compound is selected from
Aspect 36. A pharmaceutical composition comprising a compound of any one of Aspects 1-35 or a pharmaceutically acceptable salt, stereoisomer, tautomer or prodrug thereof, together with a pharmaceutically acceptable excipient.
Aspect 37. A method of decreasing EGFR activity by inhibition and/or degradation, which comprises administering to an individual the compound according to any one of Aspects 1-35, or a pharmaceutically acceptable salt thereof, including the compound of formula (I) or the specific compounds exemplified herein.
Aspect 38. The method of Aspect 37, wherein the disease is selected from cancer, preferred pancreatic cancer, breast cancer, glioblastoma multiforme, head and neck cancer, or non-small cell lung cancer.
Aspect 39. Use of a compound of any one of Aspects 1-35 or a pharmaceutically acceptable salt, stereoisomer, tautomer or prodrug thereof in the preparation of a medicament for treating a disease that can be affected by EGFR modulation.
Aspect 40. The use of Aspect 39, wherein the disease is cancer, preferred pancreatic cancer, breast cancer, glioblastoma multiforme, head and neck cancer, or non-small cell lung cancer.
Aspect 41. A method of treating a disease or disorder in a patient comprising administering to the patient a therapeutically effective amount of the compound any one of Aspects 1-35, or a pharmaceutically acceptable salt thereof as a EGFR kinase inhibitor and/or degrader, wherein the disease or disorder is associated with inhibition of EGFR.
Aspect 42. The method of Aspect 41, wherein the disease is selected from cancer, preferred pancreatic cancer, breast cancer, glioblastoma multiforme, head and neck cancer, or non-small cell lung cancer.
The following terms have the indicated meanings throughout the specification:
Unless specifically defined elsewhere in this document, all other technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this invention belongs.
The following terms have the indicated meanings throughout the specification:
As used herein, including the appended claims, the singular forms of words such as “a”. “an”, and “the”, include their corresponding plural references unless the context clearly indicates otherwise.
The term “or” is used to mean, and is used interchangeably with, the term “and/or” unless the context clearly dictates otherwise.
The term “alkyl” includes a hydrocarbon group selected from linear and branched, saturated hydrocarbon groups comprising from 1 to 18, such as from 1 to 12, further such as from 1 to 10, more further such as from 1 to 8, or from 1 to 6, or from 1 to 4, carbon atoms. Examples of alkyl groups comprising from 1 to 6 carbon atoms (i.e., C1a alkyl) include, but not limited to, methyl, ethyl, 1-propyl or n-propyl (“n-Pr”), 2-propyl or isopropyl (“i-Pr”), 1-butyl or n-butyl (“n-Bu”), 2-methyl-1-propyl or isobutyl (“i-Bu”), 1-methylpropyl or s-butyl (“s-Bu”), 1,1-dimethylethyl or t-butyl (“t-Bu”), 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl and 3,3-dimethyl-2-butyl groups.
The term “propyl” includes 1-propyl or n-propyl (“n-Pr”), 2-propyl or isopropyl (“i-Pr”).
The term “butyl” includes 1-butyl or n-butyl (“n-Bu”), 2-methyl-1-propyl or isobutyl (“i-Bu”), 1-methylpropyl or s-butyl (“s-Bu”), 1,1-dimethylethyl or t-butyl (“t-Bu”).
The term “pentyl” includes 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl.
The term “hexyl” includes 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl and 3,3-dimethyl-2-butyl.
The term “alkylene” refers to a divalent alkyl group by removing two hydrogen from alkane. Alkylene includes but not limited to methylene, ethylene, propylene, and so on.
The term “halogen” includes fluoro (F), chloro (Cl), bromo (Br) and iodo (I).
The term “alkenyl” includes a hydrocarbon group selected from linear and branched hydrocarbon groups comprising at least one C═C double bond and from 2 to 18, such as from 2 to 8, further such as from 2 to 6, carbon atoms. Examples of the alkenyl group, e.g., C2-6, alkenyl, include, but not limited to ethenyl or vinyl, prop-1-enyl, prop-2-enyl, 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, buta-1,3-dienyl, 2-methylbuta-1,3-dienyl, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl, and hexa-1,3-dienyl groups.
The term “alkenylene” refers to a divalent alkenyl group by removing two hydrogen from alkene.
Alkenylene includes but not limited to, vinylidene, butenylene, and so on.
The term “alkynyl” includes a hydrocarbon group selected from linear and branched hydrocarbon group, comprising at least one C≡C triple bond and from 2 to 18, such as 2 to 8, further such as from 2 to 6, carbon atoms. Examples of the alkynyl group, e.g., C2-6 alkynyl, include, but not limited to ethynyl, 1-propynyl, 2-propynyl (propargyl), 1-butynyl, 2-butynyl, and 3-butynyl groups.
The term “alkynylene” refers to a divalent alkynyl group by removing two hydrogen from alkyne. Alkenylene includes but not limited to ethynylene and so on.
The term “cycloalkyl” includes a hydrocarbon group selected from saturated cyclic hydrocarbon groups, comprising monocyclic and polycyclic (e.g., bicyclic and tricyclic) groups including fused, bridged or spiro cycloalkyl.
For example, the cycloalkyl group may comprise from 3 to 12, such as from 3 to 10, further such as 3 to 8, further such as 3 to 6, 3 to 5, or 3 to 4 carbon atoms. Even further for example, the cycloalkyl group may be selected from monocyclic group comprising from 3 to 12, such as from 3 to 10, further such as 3 to 8, 3 to 6 carbon atoms. Examples of the monocyclic cycloalkyl group include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, and cyclododecyl groups. In particular, examples of the saturated monocyclic cycloalkyl group, e.g., C3-8cycloalkyl, include, but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups. In a preferred embodiment, the cycloalkyl is a monocyclic ring comprising 3 to 6 carbon atoms (abbreviated as C3-6 cycloalkyl), including but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Examples of the bicyclic cycloalkyl groups include those having from 7 to 12 ring atoms arranged as a fused bicyclic ring selected from [4,4], [4,5], [5,5], [5,6] and [6,6] ring systems, or as a bridged bicyclic ring selected from bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, and bicyclo[3.2.2]nonane. Further Examples of the bicyclic cycloalkyl groups include those arranged as a bicyclic ring selected from [5,6] and [6,6] ring systems.
The term “spiro cycloalkyl” includes a cyclic structure which contains carbon atoms and is formed by at least two rings sharing one atom.
The term “fused cycloalkyl” includes a bicyclic cycloalkyl group as defined herein which is saturated and is formed by two or more rings sharing two adjacent atoms.
The term “bridged cycloalkyl” includes a cyclic structure which contains carbon atoms and is formed by two rings sharing two atoms which are not adjacent to each other. The term “7 to 10 membered bridged cycloalkyl” includes a cyclic structure which contains 7 to 12 carbon atoms and is formed by two rings sharing two atoms which are not adjacent to each other.
Examples of fused cycloalkyl, fused cycloalkenyl, or fused cycloalkynyl include but are not limited to bicyclo[1.1.0]butyl, bicyclo[2.1.0]pentyl, bicyclo[3.1.0]hexyl, bicyclo[4.1.0]heptyl, bicyclo[3.3.0]octyl, bicyclo[4.2.0]octyl, decalin, as well as benzo 3 to 8 membered cycloalkyl, benzo C4-6 cycloalkenyl, 2,3-dihydro-1H-indenyl, 1H-indenyl, 1, 2, 3, 4-tetralyl, 1,4-dihydronaphthyl, etc. Preferred embodiments are 8 to 9 membered fused rings, which refer to cyclic structures containing 8 to 9 ring atoms within the above examples.
The term “aryl” used alone or in combination with other terms includes a group selected from:
The terms “aromatic hydrocarbon ring” and “aryl” are used interchangeably throughout the disclosure herein. In some embodiments, a monocyclic or bicyclic aromatic hydrocarbon ring has 5 to 10 ring-forming carbon atoms (i.e., C5-10 aryl). Examples of a monocyclic or bicyclic aromatic hydrocarbon ring includes, but not limited to, phenyl, naphth-1-yl, naphth-2-yl, anthracenyl, phenanthrenyl, and the like. In some embodiments, the aromatic hydrocarbon ring is a naphthalene ring (naphth-1-yl or naphth-2-yl) or phenyl ring. In some embodiments, the aromatic hydrocarbon ring is a phenyl ring.
Specifically, the term “bicyclic fused aryl” includes a bicyclic aryl ring as defined herein. The typical bicyclic fused aryl is naphthalene.
The term “heteroaryl” includes a group selected from:
When the total number of S and O atoms in the heteroaryl group exceeds 1, those heteroatoms are not adjacent to one another. In some embodiments, the total number of S and O atoms in the heteroaryl group is not more than 2. In some embodiments, the total number of S and O atoms in the aromatic heterocycle is not more than 1. When the heteroaryl group contains more than one heteroatom ring member, the heteroatoms may be the same or different. The nitrogen atoms in the ring(s) of the heteroaryl group can be oxidized to form N-oxides.
Specifically, the term “bicyclic fused heteroaryl” includes a 7- to 12-membered, preferably 7- to 10-membered, more preferably 9- or 10-membered fused bicyclic heteroaryl ring as defined herein. Typically, a bicyclic fused heteroaryl is 5-membered/5-membered, 5-membered/6-membered, 6-membered/6-membered, or 6-membered/7-membered bicyclic. The group can be attached to the remainder of the molecule through either ring.
“Heterocyclyl”, “heterocycle” or “heterocyclic” are interchangeable and include a non-aromatic heterocyclyl group comprising one or more heteroatoms selected from nitrogen, oxygen or optionally oxidized sulfur as ring members, with the remaining ring members being carbon, including monocyclic, fused, bridged, and spiro ring, i.e., containing monocyclic heterocyclyl, bridged heterocyclyl, spiro heterocyclyl, and fused heterocyclic groups.
The term “at least one substituent” disclosed herein includes, for example, from 1 to 4, such as from 1 to 3, further as 1 or 2, substituents, provided that the theory of valence is met. For example. “at least one substituent F” disclosed herein includes from 1 to 4, such as from 1 to 3, further as 1 or 2, substituents F.
The term “divalent” refers to a linking group capable of forming covalent bonds with two other moieties. For example, “a divalent cycloalkyl group” refers to a cycloalkyl group obtained by removing two hydrogen from the corresponding cycloalkane to form a linking group, the term “divalent aryl group”, “divalent heterocycyl group” or “divalent heteroaryl group” should be understood in a similar manner.
Compounds disclosed herein may contain an asymmetric center and may thus exist as enantiomers. “Enantiomers” refer to two stereoisomers of a compound which are non-superimposable mirror images of one another. Where the compounds disclosed herein possess two or more asymmetric centers, they may additionally exist as diastereomers. Enantiomers and diastereomers fall within the broader class of stereoisomers. All such possible stereoisomers as substantially pure resolved enantiomers, racemic mixtures thereof, as well as mixtures of diastereomers are intended to be included. All stereoisomers of the compounds disclosed herein and/or pharmaceutically acceptable salts thereof are intended to be included. Unless specifically mentioned otherwise, reference to one isomer applies to any of the possible isomers. Whenever the isomeric composition is unspecified, all possible isomers are included.
When compounds disclosed herein contain olefinic double bonds, unless specified otherwise, such double bonds are meant to include both E and Z geometric isomers.
When compounds disclosed herein contain a di-substituted cyclic ring system, substituents found on such ring system may adopt cis and trans formations. Cis formation means that both substituents are found on the upper side of the 2 substituent placements on the carbon, while trans would mean that they were on opposing sides. For example, the di-substituted cyclic ring system may be cyclohexyl or cyclobutyl ring.
It may be advantageous to separate reaction products from one another and/or from starting materials. The desired products of each step or series of steps is separated and/or purified (hereinafter separated) to the desired degree of homogeneity by the techniques common in the art. Typically such separations involve multiphase extraction, crystallization from a solvent or solvent mixture, distillation, sublimation, or chromatography. Chromatography can involve any number of methods including, for example: reverse-phase and normal phase; size exclusion; ion exchange; high, medium and low pressure liquid chromatography methods and apparatus; small scale analytical; simulated moving bed (“SMB”) and preparative thin or thick layer chromatography, as well as techniques of small scale thin layer and flash chromatography. One skilled in the art could select and apply the techniques most likely to achieve the desired separation.
“Diastereomers” refer to stereoisomers of a compound with two or more chiral centers but which are not mirror images of one another. Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereoisomers to the corresponding pure enantiomers. Enantiomers can also be separated by use of a chiral HPLC column.
A single stereoisomer, e.g., a substantially pure enantiomer, may be obtained by resolution of the racemic mixture using a method such as formation of diastereomers using optically active resolving agents (Eliel, E and Wilen, S Stereochemistry of Organic Compounds. New York: John Wiley & Sons, Inc., 1994; Lochmuller, C. H., et al. “Chromatographic resolution of enantiomers: Selective review.” J. Chromatogr., 113(3) (1975): pp, 283-302). Racemic mixtures of chiral compounds of the invention can be separated and isolated by any suitable method, including: (1) formation of ionic, diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods, (2) formation of diastereomeric compounds with chiral derivatizing reagents, separation of the diastereomers, and conversion to the pure stereoisomers, and (3) separation of the substantially pure or enriched stereoisomers directly under chiral conditions. See: Wainer, Irving W., Ed Drug Stereochemistry: Analytical Methods and Pharmacology. New York: Marcel Dekker, Inc., 1993.
Some of the compounds disclosed herein may exist with different points of attachment of hydrogen, referred to as tautomers. For example, compounds including carbonyl —CH2C(O)— groups (keto forms) may undergo tautomerism to form hydroxyl —CH═C(OH)— groups (enol forms). Both keto and enol forms, individually as well as mixtures thereof, are also intended to be included where applicable.
“Prodrug” refers to a derivative of an active agent that requires a transformation within the body to release the active agent. In some embodiments, the transformation is an enzymatic transformation. Prodrugs are frequently, although not necessarily, pharmacologically inactive until converted to the active agent.
“Pharmaceutically acceptable salts” refer to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. A pharmaceutically acceptable salt may be prepared in situ during the final isolation and purification of the compounds disclosed herein, or separately by reacting the free base function with a suitable organic acid or by reacting the acidic group with a suitable base. The term also includes salts of the stereoisomers (such as enantiomers and/or diastereomers), tautomers and prodrugs of the compound of the invention.
In addition, if a compound disclosed herein is obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, such as a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize various synthetic methodologies that may be used without undue experimentation to prepare non-toxic pharmaceutically acceptable addition salts.
The terms “administration”, “administering”, “treating” and “treatment” herein, when applied to an animal, human, experimental subject, cell, tissue, organ, or biological fluid, mean contact of an exogenous pharmaceutical, therapeutic, diagnostic agent, or composition to the animal, human, subject, cell, tissue, organ, or biological fluid. Treatment of a cell encompasses contact of a reagent to the cell, as well as contact of a reagent to a fluid, where the fluid is in contact with the cell. The term “administration” and “treatment” also means in vitro and ex vivo treatments, e.g., of a cell, by a reagent, diagnostic, binding compound, or by another cell. The term “subject” herein includes any organism, preferably an animal, more preferably a mammal (e.g., rat, mouse, dog, cat, and rabbit) and most preferably a human.
The term “effective amount” or “therapeutically effective amount” refers to an amount of the active ingredient, such as compound that, when administered to a subject for treating a disease, or at least one of the clinical symptoms of a disease or disorder, is sufficient to affect such treatment for the disease, disorder, or symptom. The term “therapeutically effective amount” can vary with the compound, the disease, disorder, and/or symptoms of the disease or disorder, severity of the disease, disorder, and/or symptoms of the disease or disorder, the age of the subject to be treated, and/or the weight of the subject to be treated. An appropriate amount in any given instance can be apparent to those skilled in the art or can be determined by routine experiments. In some embodiments, “therapeutically effective amount” is an amount of at least one compound and/or at least one stereoisomer, tautomer or prodrug thereof, and/or at least one pharmaceutically acceptable salt thereof disclosed herein effective to “treat” as defined herein, a disease or disorder in a subject. In the case of combination therapy, the term “therapeutically effective amount” refers to the total amount of the combination objects for the effective treatment of a disease, a disorder or a condition.
The term “disease” refers to any disease, discomfort, illness, symptoms or indications, and can be interchangeable with the term “disorder” or “condition”.
Throughout this specification and the claims which follow, unless the context requires otherwise, the term “comprise”, and variations such as “comprises” and “comprising” are intended to specify the presence of the features thereafter, but do not exclude the presence or addition of one or more other features. When used herein the term “comprising” can be substituted with the term “containing”, “including” or sometimes “having”.
Throughout this specification and the claims which follow, the term “Cn-m˜” indicates a range which includes the endpoints, wherein n and m are integers and indicate the number of carbons. Examples include C1-8, C1-6, and the like.
Unless specifically defined elsewhere in this document, all other technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this invention belongs.
The examples below are intended to be purely exemplary and should not be considered to be limiting in any way. Efforts have been made to ensure accuracy with respect to numbers used (for example, amounts, temperature, etc.), but some experimental errors and deviations should be accounted for. Unless indicated otherwise, temperature is in degrees Centigrade. Reagents were purchased from commercial suppliers such as Sigma-Aldrich, Alfa Aesar, or TCI, and were used without further purification unless indicated otherwise. Unless indicated otherwise, the reactions set forth below were performed under a positive pressure of nitrogen or argon or with a drying tube in anhydrous solvents; the reaction flasks were fitted with rubber septa for the introduction of substrates and reagents via syringe; and glassware was oven dried and/or heat dried.
1H NMR spectra were recorded on an Agilent instrument operating at 400 MHz. 1HNMR spectra were obtained using CDCl3, CD2Cl2, CD3OD, D2O, d6-DMSO, d6-acetone or (CD3)2CO as solvent and tetramethylsilane (0.00 ppm) or residual solvent (CDCl3: 7.25 ppm; CD3OD: 3.31 ppm; D2O: 4.79 ppm; d6-DMSO: 2.50 ppm; d6-acetone: 2.05; (CD3)3CO: 2.05) as the reference standard. When peak multiplicities are reported, the following abbreviations are used: s (singlet), d (doublet), t (triplet), q (quartet), qn (quintuplet), sx (sextuplet), m (multiplet), br (broadened), dd (doublet of doublets), dt (doublet of triplets). Coupling constants, when given, are reported in Hertz (Hz).
LCMS-1: LC-MS spectrometer (Agilent 1260 Infinity) Detector: MWD (190-400 nm), Mass detector: 6120 SQ Mobile phase: A: water with 0.1% Formic acid, B: acetonitrile with 0.1% Formic acid Column: Poroshell 120 EC-C18, 4.6×50 mm, 2.7 pm Gradient method: Flow: 1.8 mL/min Time (min) A (%) B (%)
LCMS, LCMS-3: LC-MS spectrometer (Agilent 1260 Infinity II) Detector: MWD (190400 nm). Mass detector: G6125C SQ Mobile phase: A: water with 0.1% Formic acid, B: acetonitrile with 0.1% Formic acid Column: Poroshell 120 EC-C18, 4.6×50 mm, 2.7 pm Gradient method: Flow: 1.8 mL/min Time (min) A (%) B (%)
LCMS-2: LC-MS spectrometer (Agilent 1290 Infinity II) Detector: MWD (190-400 nm). Mass detector: G6125C SQ Mobile phase: A: water with 0.1% Formic acid, B: acetonitrile with 0.1% Formic acid Column: Poroshell 120 EC-C18, 4.6×50 mm, 2.7 pm Gradient method: Flow: 1.2 mL/min Time (min) A (%) B (%)
Preparative HPLC was conducted on a column (150×21.2 mm ID, 5 pm, Gemini NXC 18) at a flow rate of 20 ml/min, injection volume 2 ml, at room temperature and UV Detection at 214 nm and 254 nm.
In the following examples, the abbreviations below are used:
To a solution of 1-((6-amino-2-methylquinolin-5-yl)-2,5-dihydrophosphole 1-oxide (800 mg, 3.1 mmol) in MeOH (20 mL) was added Pd/C (10%, wet, 100 mg). The resulting solution was stirred for 12 h at room temperature under H2 atmosphere (1-2 atm). Pd/C was filtered out, the filtrate was evaporated to dryness. 1-(6-amino-2-methylquinolin-5-yl)phospholane 1-oxide (720 mg, 89.3%) was obtained and used to the next step without further purification. [M+H]+=261.1.
To a solution of 1-(6-amino-2-methylquinolin-5-yl)phospholane 1-oxide (720 mg, 2.8 mmol) in THF (20 mL) was added 5-bromo-2,4-dichloropyrimidine (1.6 g, 6.9 mmol) at 0° C. And then LiHMDS (1 M, 5.5 mL, 5.5 mmol) was added to the reaction mixture at 0° C. The mixture was stirred at 20° C., for 3 hrs. Water (10 mL) was poured into the mixture, which was further extracted with DCM (20 mL×3). The combined organic phase was washed with brine (20 mL), dried over Na2SO4, filtered and concentrated in vacuum. The residue was purified by column chromatography (DCM/MeOH=10/1 to 5/1) to afford 1-(6-((5-bromo-2-chloropyrimidin-4-yl)amino)-2-methylquinolin-5-yl)phospholane 1-oxide (680 mg, 54.4%). [M+H]+=451.0.
A mixture of 1-bromo-2-fluoro-4-methoxy-5-nitrobenzene (4 g, 16 mmol), tert-butyl 4-(piperidin-4-yl)piperazine-1-carboxylate (6.4 g, 24 mmol), K2CO3 (4.4 g, 32 mmol) in DMF (50 mL) was stirred in a flask at 80° C. overnight. The reaction mixture was allowed to cool down to room temperature. The resulting mixture was diluted with water and extracted with EtOAc (3×500 mL). The combined organic layers were washed with brine (500 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE/EtOAc (1:1) to afford the product (7 g, 90%). [M+H]+=499.1.
Step 4: tert-butyl 4-(1-(5-methoxy-4-nitro-2-vinylphenyl)piperidin-4-yl)piperazine-1-carboxylate
A mixture of tert-butyl 4-(1-(2-bromo-5-methoxy-4-nitrophenyl)piperidin-4-yl)piperazine-1-carboxylate (7 g, 14 mmol), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (4.3 g, 28 mmol), Pd(dppf)Cl2 (1.1 g, 1.4 mmol) and K3PO4 (8.9 g, 42 mmol) in DMF (160 mL) and water (20 mL) was stirred in a flask at 90° C. under nitrogen atmosphere for 16 hrs. The reaction mixture was allowed to cool down to room temperature. The resulting mixture was extracted with EtOAc (3×1000 mL). The combined organic layers were washed with brine (50) mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE/EtOAc (1:1) to afford the product (5 g, 80%). [M+H]+=447.0.
To a stirred solution of tert-butyl 4-(1-(5-methoxy-4-nitro-2-vinylphenyl)piperidin-4-yl)piperazine-1-carboxylate (5 g, 11.2 mmol) in MeOH (100 mL) and DCM (20.00 mL) was added Pd/C (wet, 10%) (1 g) under nitrogen atmosphere. The resulting mixture was stirred for 16 hrs at room temperature under hydrogen atmosphere. The resulting mixture was filtered, the filter cake was washed with DCM/CH3OH (10:1, 200 mL). The filtrate was concentrated under reduced pressure to afford the product (4.0 g, 85.3%). [M+H]+=419.1.
To a solution of 1-(6-((5-bromo-2-chloropyrimidin-4-yl)amino)-2-methylquinolin-5-yl)phospholane 1-oxide (680 mg, 1.5 mmol) in n-BuOH (20 mL) was added tert-butyl 4-(1-(4-amino-2-ethyl-5-methoxyphenyl)piperidin-4-yl)piperazine-1-carboxylate (633 mg, 1.5 mmol) at 20° C. 4-methylbenzenesulfonic acid (774 mg, 4.5 mmol) was added to the reaction mixture at 20° C. Then the mixture was stirred at 90° C. for 15 hrs. The reaction mixture was evaporated to dryness, water (20 mL) was poured into the mixture. Then the mixture was adjusted to pH=8 with sat. aq. NaHCO3 solution and extracted with DCM (20 mL×3). The organic phase was washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated in vacuum. The residue was purified by column chromatography (DCM/MeOH=10/1 to 5/1) to afford 1-(6-((5-bromo-2-((5-ethyl-2-methoxy-4-(4-(piperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-2-methylquinolin-5-yl)phospholane 1-oxide (580 mg, 52.3%). [M+H]+=733.3.
A mixture of 2,6-bis(benzyloxy)-3-bromopyridine (15 g, 40.65 mmol) and 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (12.6 g, 49.61 mmol), Pd(dppf)Cl2 (3.32 g, 4.07 mmol), KOAc (12 g, 122.45 mmol) in dioxane (200 mL) was stirred overnight at 100° C. under nitrogen atmosphere. The resulting mixture was filtered, the filter cake was washed with MeOH and DCM. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE/EtOAc (8:1) to afford the product (9.00 g, 53%). [M+H]+=418.3.
A mixture of 2,6-bis(benzyloxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (9.00 g, 21.56 mmol) and 5-bromo-1,3-difluoro-2-iodobenzene (6.88 g, 21.57 mmol), K2CO3 (10.43 g, 75.48 mmol), Pd(dppf)Cl2 (789 mg, 1.078 mmol) in dioxane (90 mL) and H2O (30 mL) was stirred for 16 h at 100° C. under nitrogen atmosphere. The resulting mixture was extracted with EtOAc (50 mL×3). The combined organic layers were washed with brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE/EtOAc (5:1) to afford the product (4 g, 38%). [M+H]+=482.4.
To a solution of 2,6-bis(benzyloxy)-3-(4-bromo-2,6-difluorophenyl)pyridine (1 g, 2.07 mmol), methyl (R)-pyrrolidine-3-carboxylate hydrochloride (495 mg, 3 mmol) and Cs2CO3 (1.95 g, 6 mmol) in 10 mL DMSO, Pd2(dba)3 (183 mg, 0.2 mmol) and Xantphos (231 mg, 0.4 mmol) was added wider N2 atmosphere. The mixture was stirred at 90° C. for 16 hours under N2 atmosphere. After LCMS showed the reaction was completed. The mixture was diluted with EtOAc (100 mL) and washed with brine (100 mL×2). The organic phase was dried over Na2SO4, filtered and concentrated in vacuum. The residue was purified by silica column chromatography (PE:EA=10:1) to afford product (740 mg, 67.4% yield). [M+H]+=530.8.
To a solution of methyl (R)-1-(4-(2,6-bis(benzyloxy)pyridin-3-yl)-3,5-difluorophenyl)pyrrolidine-3-carboxylate (740 mg, 1.4 mmol) in 10 mL THF. LiOH·H2O (84 mg, 2 mmol) in 2 mL water was added. The mixture was stirred at 25° C. for 2 hours. After LCMS showed the reaction was completed. The mixture was concentrated in vacuum. The residue was adjust pH<5 with 1 N HCl and extracted with 50 mL EtOAc. The organic phase was dried over Na2SO4, filtered and concentrated in vacuum to afford product (700 mg, 96.9% yield). [M+H]+=516.8.
To a solution of (R)-1-(4-(2,6-bis(benzyloxy)pyridin-3-yl)-3,5-difluorophenyl)pyrrolidine-3-carboxylic acid (700 mg, 1.35 mmol) in 5 mL DCM and 30 mL MeOH, 350 mg Pd/C was added. The mixture was stirred at 30° C. for 16 hours under H2 atmosphere. After LCMS showed the reaction was completed and the mixture was filtered. The organic phase was concentrated in vacuum to afford product (350 mg, 76.7% yield). [M+H]+=338.8.
To a solution of 1-(6-((5-bromo-2-((5-ethyl-2-methoxy-4-(4-(piperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-2-methylquinolin-5-yl)phospholane-1-oxide (50 mg, 0.07 mmol), (3R)-1-(4-(2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)pyrrolidine-3-carboxylic acid (35 mg, 0.1 mmol) and DIEA (26 mg, 0.2 mmol) in 10 mL DCM, 50% w.t. T3P in EtOAc solution (64 mg, 0.1 mmol) was added. The mixture was stirred at 25° C. for 16 hours. When LCMS showed the reaction was completed, the mixture was quenched with water (10 mL). The organic phase was concentrated in vacuum and purified by prep-HPLC with C-18 column chromatography (0.1% FA in water:acetonitrile=90:10˜50:50 gradient elution) to afford product (18.2 mg, 25.3% yield). 1H NMR (500 MHz, DMSO) δ 11.31 (s, 1H), 10.84 (s, 1H), 8.32 (s, 1H), 8.22 (s, 1H), 8.03 (s, 1H), 7.94 (dd, J=13.9, 9.3 Hz, 2H), 7.29-7.47 (m, 2H), 6.75 (s, 1H), 6.18 (dd, J=44.0, 21.4 Hz, 4H), 4.02 (dd, J=12.5, 4.9 Hz, 1H), 3.78 (s, 3H), 3.43-3.56 (m, 7H), 3.24-3.28 (m, 4H), 2.94-3.04 (m, 4H), 2.73-2.88 (m, 3H), 2.52-2.71 (m, 9H), 2.47-2.49 (m, 1H), 2.23-2.43 (m, 3H), 2.02-2.21 (m, 3H), 1.89-2.00 (m, 1H), 1.83 (d, J=10.4 Hz, 2H), 1.49-1.63 (m, 2H), 0.78 (s, 3H). [M+H]+=1053.4.
To a solution of allylmagnesium bromide (310 mL, 1M in Et2O, 0.35 mol) in Et2O (200 mL) was added diethyl phosphonate (12 g dissolved in Et2O, 87 mmol) dropwise in 30 min at −20 degrees C. the reaction solution was stirred for 30 min at this temperature, then allowed the temperature rise to room temperature naturally. Then the mixture was stirred at 100° C. for 14 hrs. The reaction was quenched by the addition of Sat.NH4Cl, extracted with Et2O (100 mL×2), combined the organic layer and washed with brine, dried over anhydrous Na2SO4, after filtration, the filtrate was concentrated under reduced pressure to afford the product (3.1 g, 27.2%). [M+H]+=131.1.
To a solution of 2-iodoaniline (2 g, 9.1 mmol) and diallylphosphine oxide (2.4 g, 18.3 mmol) in dioxane (50 mL) was added K3PO4 (4.8 g, 22.7 mmol), then Pd(OAc)2 (205 mg, 0.91 mmol) and Xantphos (528 mg, 0.91 mmol) were added to the mixture at 20° C. The suspension was degassed under vacuum and purged with N2 three times. Then the mixture was stirred at 100° C. for 4 hrs. The mixture was filtered and concentrated in vacuum. The residue was purified by column chromatography (DCM/MeOH=20/1 to 10/1) to afford diallyl(2-aminophenyl)phosphine oxide (1.2 g, 60%). [M+H]+=222.1.
To a solution of diallyl(2-aminophenyl)phosphine oxide (1.2 g, 5.4 mmol) in DCM (200 mL) was added Grubbs 2nd generation catalyst (918 mg, 1.1 mmol). The reaction mixture was stirred for 16 h at room temperature. The mixture was concentrated in vacuum. The residue was purified by column chromatography (DCM/MeOH=20/1 to 10/1) to afford 1-(2-aminophenyl)-2,5-dihydrophosphole 1-oxide (750 mg, 71.4%). m/z [M+H]+=194.1.
To a solution of 1-(2-aminophenyl)-2,5-dihydrophosphole 1-oxide (750 mg, 3.9 mmol) in MeOH (20 mL) was added Pd/C (10%, wet, 100 mg). The resulting solution was stirred for 12 h at room temperature under H2 atmosphere (1-2 atm). Pd/C was filtered out, the filtrate was evaporated to dryness, 1-(2-aminophenyl)phospholane 1-oxide (720 mg, 95%) was obtained and used to the next step without further purification. m/z [M+H]+=196.1.
To a solution of 1-(2-aminophenyl)phospholane 1-oxide (720 mg, 3.7 mmol) in THF (15 mL) was added 5-bromo-2,4-dichloropyrimidine (2.1 g, 9.2 mmol) at 0° C. And then LiHMDS (1 M, 7.4 mL, 7.4 mmol) was added to the reaction mixture at 0° C. The mixture was stirred at 20° C. for 3 hrs. Water (10 mL) was poured into the mixture, which was further extracted with DCM (20 mL×3). The combined organic phase was washed with brine (20 mL), dried over Na2SO4, filtered and concentrated in vacuum. The residue was purified by column chromatography (DCM/MeOH=10/1 to 5/1) to afford 1-(2-((5-bromo-2-chloropyrimidin-4-yl)amino)phenyl)phospholane 1-oxide (620 mg, 43%). [M+H]+=386.0.
To a solution of 1-(2-((5-bromo-2-chloropyrimidin-4-yl)amino)phenyl)phospholane 1-oxide (620 mg, 1.6 mmol) in n-BuOH (20 mL) was added tert-butyl 4-(1-(4-amino-2-ethyl-5-methoxyphenyl)piperidin-4-yl)piperazine-1-carboxylate (671 mg, 1.6 mmol) at 20° C. 4-methylbenzenesulfonic acid (826 mg, 4.8 mmol) was added to the reaction mixture at 20° C. Then the mixture was stirred at 90° C. for 15 hrs. The reaction mixture was evaporated to dryness, water (20 mL) was poured into the mixture. Then the mixture was adjusted to pH=8 with sat. aq. NaHCO3 solution and extracted with DCM (20 mL×3). The organic phase was washed with brine (30 mL), dried over Na2SO4, filtered and concentrated in vacuum. The residue was purified by column chromatography (DCM/MeOH=10/1 to 5/1) to afford 1-(2-((5-bromo-2-((5-ethyl-2-methoxy-4-(4-(piperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)phospholane 1-oxide (510 mg, 47.7%). [M+H]+=668.2.
A solution of 1,3-difluoro-2-nitrobenzene (50.0 g, 314.4 mmol) in NMP (300 mL) were cooled to −20° C. under N2 atmosphere. Then a mixture of ethyl 2-chloroacetate (65.5 g, 534.7 mmol) and t-BuOK (121.0 g, 1.08 mol) in NMP (50 mL) was added slowly at −10° C. to −20° C. over 2 h. After being stirred for 2 h, the reaction was quenched by pouring into 1M HCl (200 mL) and ice-water. The mixture was extracted with EA (300 mL×3). The combined organic layer was washed by brine, dried with Na2SO4. The solution was concentrated in vacuum and the residue was purified by silica gel column chromatography (PE/EA=200/1 to 100/1) to provide product (13.7 g, 18%). 1H NMR (400 MHz, CDCl3) δH 7.06 (d, J=8.4 Hz, 2H), 4.20 (q, J=7.2 Hz, 2H), 3.65 (s, 2H), 1.28 (t, J=7.2 Hz, 3H).
To a solution of ethyl 2-(3,5-difluoro-4-nitrophenyl)acetate (13.7 g, 56 mmol) in MeOH (150 mL) was added 10% Pd/C (1.5 g) at r.t. The mixture was stirred at r.t under H2 atmosphere for 5 h. Filtrated on vacuum to remove Pd/C and concentrated in vacuum to provide the product (12.2 g), which was used in next step without further purification. 1H NMR (400 MHz, DMSO_d6) δH 6.82 (d, J=8.0 Hz, 2H), 5.69 (s, 2H), 4.06 (q, J=7.2 Hz, 2H), 3.52 (s, 2H), 1.17 (t, J=7.2 Hz, 3H). [M+H]+=216.4.
A solution of ethyl 2-(4-amino-3,5-difluorophenyl)acetate (12.2 g, 56 mmol) in MeCN (150 mL) was cooled to 0° C. under N2 atmosphere and CuI (21.2 g, 112 mmol) was added. After stirring for 10 min, tert-butylnitrite (11.5 g, 112 mmol) was added dropwise over 30 min. Then the mixture was stirred at r.t for overnight. The reaction was quenched by pouring into water and extracted with EA (300 mL×3). All organic layers were combined and washed by brine, dried with Na2SO4. The solution was concentrated in vacuum and the residue was purified by silica gel column chromatography (PE/EA=500/1 to 100/1) to provide the product (8.8 g, 48%). [M+H]+=326.5.
To a solution of ethyl 2-(3,5-difluoro-4-iodophenyl)acetate (8.8 g, 27.0 mmol) in a mixed solvent of 1,4-dioxane/H2O (100 mL/20 mL) were added K2CO3 (9.3 g, 67.4 mmol), 2,6-bis(benzyloxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (14.6 g, 35.0 mol) and Pd(dppf)Cl2 (2.9 g, 4.0 mmol) under N2 atmosphere. The resulting solution was stirred for 6 h at 100° C. The mixture was diluted with water (300 mL) and extracted with EA (300 mL×3). All organic layers were combined and washed with brine (300 mL), dried over Na2SO4. The solution was concentrated in vacuum and the residue was purified by silica gel column chromatography (PE/EA=200/1) to give the product (8.2 g, 62%). 1H NMR (40) MHz, CDCl3) &a 7.49 (d, J=8.0 Hz, 1H), 7.40-7.24 (m, 10H), 6.90 (d, J=8.0 Hz, 2H), 6.47 (d, J=8.0 Hz, 1H), 5.38 (s, 2H), 5.33 (s, 2H), 4.19 (q, J=7.2 Hz, 2H), 3.61 (s, 2H), 1.28 (t, J=7.2 Hz, 3H).
A solution of ethyl 2-(4-(2,6-bis(benzyloxy)pyridin-3-yl)-3,5-difluorophenyl)acetate (8.2 g, 16.7 mol) in THF (100 mL) was cooled to 0° C. under N2 atmosphere and 1.5 M DIBAL-H (45 mL, 67.5 mol) in THF was added dropwise over 30 min. Then the mixture was stirred at r.t for 2 h. The reaction was quenched by pouring into water and extracted with EA (300 mL×3). All organic layers were combined and washed by brine, dried with Na2SO4. The solution was concentrated in vacuum and the residue was purified by column chromatography (PE/EA=10/1 to 3/1) to provide the product (6.6 g, 88%). 1H NMR (400 MHz, CDCl3) δH 7.49 (d, J=8.0 Hz, 1H), 7.42-7.25 (m, 9H), 6.84 (d, J=8.0 Hz, 2H), 6.47 (d, J=8.0 Hz, 1H), 5.38 (s, 2H), 5.33 (s, 2H), 3.90 (m, 2H), 2.87 (t, J=6.4 Hz, 2H). [M+H]+=448.3.
To a solution of 2-(4-(2,6-bis(benzyloxy)pyridin-3-yl)-3,5-difluorophenyl)ethanol (6.6 g, 14.7 mmol) in DCM (150 mL) was added TFA (50 mL). After stirred overnight, the mixture was concentrated in vacuo. The residue was dissolved in MeOH (200 mL) and 10% Pd/C (1.0 g) was added. The resulted mixture was stirred for 2 days at r.t under H2 atmosphere. The mixture was filtered and the filtrate was concentrated to give a residue which was purified by reversed flash C18 chromatography (ACN/water=0% to 30%) to give the title compound (2.1 g, 53%). [M+H]+=270.1.
A mixture of 3-(2,6-difluoro-4-(2-hydroxyethyl)phenyl)piperidine-2,6-dione (86.4 mg, 0.32 mmol) and IBX (132 mg, 0.47 mmol) in DMSO (10 mL) was stirred in a flask at room temperature overnight. The reaction was quenched with water and the mixture was extracted with EtOAc, washed three times with saturated aqueous NaCl and twice with saturated aqueous NaHCO3. The organic layer was dried over anhydrous Na2SO4 and evaporated in vacuum to afford the product (61 mg, 71%). [M+H]+=268.1.
To a solution of 1-(2-((5-bromo-2-((5-ethyl-2-methoxy-4-(4-(piperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)phospholane 1-oxide (50 mg, 0.075 mmol) in DCM (3 mL) was added 2-(4-(2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)acetaldehyde (40 mg, 0.15 mmol) at 20° C. The mixture was stirred at 20° C. for 1 hr and STAB (32 mg, 0.15 mmol) was added. Then the mixture was stirred at 20° C. for 2 hrs. Water (10 mL) was poured into the mixture. Then the mixture was extracted with DCM (20 mL). The organic phase was washed with brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC (C-18 column chromatography (0.1% FA in water:acetonitrile=90:10˜60:40 gradient elution) to afford the product (17.7 mg, 17.6%). 1H NMR (500 MHz, DMSO) δ 10.88 (s, 1H), 10.50 (s, 1H), 8.15 (d, J=27.9 Hz, 2H), 7.98 (s, 1H), 7.42 (dd, J=13.4, 7.7 Hz, 1H), 7.36 (s, 1H), 7.30 (t, J=7.6 Hz, 1H), 7.10 (t, J=7.4 Hz, 1H), 6.96 (d, J=10.2 Hz, 2H), 6.69 (s, 1H), 4.13 (dd, J=12.6, 5.0 Hz, 1H), 3.69 (s, 3H), 2.92 (d, J=10.8 Hz, 2H), 2.65-2.80 (m, 6H), 2.46-2.60 (m, 6H), 2.21-2.41 (m, 6H), 1.73-2.10 (m, 13H), 1.39-1.60 (m, 2H), 0.85-1.02 (m, 3H). [M+H]+=919.3.
To a solution of 4-ethyl-3-fluorophenol (35 g, 0.25 mol) in DMF (200 mL) was added K2CO3 (69, 0.5 mol). EtI (50.7 g, 0.32 mol). The mixture was stirred at 20-30° C. for 18 hours. The reaction was quenched by H2O (200 mL) and extracted with EA (150 mL*2). The organic phase was combined and washed with brine (300 mL*3). The organic phase was concentrated and purified by a silica gel column, eluted with PE (100%) to give product (35 g, yield: 83.3%). [M+H]+=169.2.
To a solution of 4-ethoxy-1-ethyl-2-fluorobenzene (35 g, 0.2 mol) in Ac2O (100 mL) was added conc. HNO3 (25.2 g, 0.26 mol, 65%) dropwise at 0° C. The mixture was stirred at r.t. for 2 hs. The reaction was quenched with Na2CO3 solution (500 mL). Product was isolated by filtration. (25 g, yield: 58.7%). 1H NMR (500 MHz, d-DMSO) δ 7.90 (d, J=8.0 Hz, 1H), 7.26 (d, J=12.0 Hz, 1H), 4.2 (q, J=7.0 Hz, 2H), 2.60 (q, J=7.5 Hz, 2H), 1.33 (t, J=7.0 Hz, 3H), 1.15 (t, J=7.5 Hz, 3H).
To a solution of 1-ethoxy-4-ethyl-5-fluoro-2-nitrobenzene (20 g, 94 mmol) in DMF (300 mL) was added tert-butyl 4-(piperidin-4-yl)piperazine-1-carboxylate (30 g, 112 mmoL), K2CO3 (32 g, 235 mmol). The mixture was stirred at 120° C. for 28 hours. The mixture was poured into ice water. The product was isolated by filtration. (20 g, yield: 46.1%). [M+H]+=: 463.2. 1H NMR (500 MHz, d-DMSO) δ 7.74 (s, 1H), 6.73 (s, 1H), 4.19 (q, J=7.0 Hz, 2H), 3.30 (br, 4H), 3.23 (d, J=11.0 Hz, 2H), 2.71 (t, J=11.5 Hz, 2H), 2.57 (q, J=7.5 Hz, 2H), 2.47 (br, 4H), 2.39 (t, J=11.0 Hz, 1H), 1.84 (d, J=11.5 Hz, 2H), 1.58 (q, J=10.5 Hz, 2H), 1.39 (s, 9H), 1.34 (t, J=7.5 Hz, 3H), 1.19 (t, J=7.5 Hz, 3H).
To a solution of tert-butyl 4-(1-(5-ethoxy-2-ethyl-4-nitrophenyl)piperidin-4-yl)piperazine-1-carboxylate (20 g, 94 mmol) in THF (150 mL) was added Pd/C (2 g). The mixture was stirred at r.t. under H2 (1 atm) for 48 hs. The solid was filtered off. The filtrate was concentrated for next step directly without further operation. [M+H]+=433.4.
The titled compound was synthesized in a manner similar to that in Example 77 Step 6 from 1-(6-((5-bromo-2-chloropyrimidin-4-yl)amino)-2-methylquinolin-5-yl)phospholane 1-oxide and tert-butyl 4-(1-(4-amino-5-ethoxy-2-ethylphenyl)piperidin-4-yl)piperazine-1-carboxylate. [M+H]+=747.2.
The titled compound was synthesized in a manner similar to that in Example 147 Step 14 from 1-(6-((5-bromo-2-((2-ethoxy-5-ethyl-4-(4-(piperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-2-methylquinolin-5-yl)phospholane 1-oxide and 2-(4-(2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)acetaldehyde. 1H NMR (500 MHz, DMSO) δ 10.88 (s, 1H), 10.48 (s, 1H), 8.65 (d, J=8.7 Hz, 1H), 8.17 (s, 1H), 7.89-7.94 (m, 2H), 7.74 (s, 1H), 7.42 (dd, J=13.2, 8.5 Hz, 1H), 7.32 (s, 11H), 6.95 (d, J=10.0 Hz, 2H), 6.59 (s, 1H), 4.13 (dd, J=12.6, 5.0 Hz, 1H), 3.93 (q, J=7.0 Hz, 2H), 2.64-2.83 (m, 5H), 2.60 (s, 3H), 2.44-2.55 (m, 8H), 2.28-2.40 (m, 4H), 1.80-2.21 (m, 14H), 1.73 (d, J=10.9 Hz, 2H), 1.32-1.48 (m, 2H), 1.21 (t, J=6.9 Hz, 3H), 0.47 (s, 3H). [M+H]+=998.4.
To a solution of 6-bromo-N1-methylbenzene-1,2-diamine (4 g, 19.9 mmol) in CH3CN (50 mL) was added CDI (6.4 g, 39.8 mmol). The resulting solution was stirred for 6 h at 90° C. under nitrogen atmosphere. The solid was collected by filtration. This was resulted in 7-bromo-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (4.1 g, 90.7%). [M+H]+=227.0.
To a solution of 7-bromo-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (600 mg, 2.6 mmol) in THF (10 mL) was added t-BuOK (1M in THF, 3.2 mL, 3.1 mmol) dropwise in 10 min at 0° C., the reaction solution was stirred for 30 min at this temperature, then to this was added 1-(4-methoxybenzyl)-2,6-dioxopiperidin-3-yl trifluoromethanesulfonate (1.1 g, 2.9 mmol) in THF (5 mL) dropwise in 10 min. The resulting solution was stirred for 2 h at 0-10° C. The reaction was quenched by the addition of sat.aq. NH4Cl solution, extracted with EtOAc (10 mL×3), combined the organic layer, and washed with brine, dried over anhydrous Na2SO4, after filtration, the filtrate was concentrated under reduced pressure. The residue was purified by a silica gel column, eluted with PE/EtOAc (1:1) to afford product (910 mg, 75.2%). [M+H]+=458.1.
3-(4-bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-1-(4-methoxybenzyl)piperidine-2,6-dione (800 mg, 1.75 mmol) was dissolved in MeSO2H/toluene (2 mL/6 mL). The resulting mixture was stirred for 3 h at 100° C. Solvent was removed and the residue was poured into ice/water. The solid was collected by filtration. 3-(4-bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione was obtained (510 mg, 86.4%). [M+H]+=338.1.
To a stirred solution of 3-(4-bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (250 mg, 0.74 mmol) and (E)-2-(2-ethoxyvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (176 mg, 0.89 mmol) in DMF/H2O (8 mL/2 mL) were added Pd(dtbpf)Cl2 (48 mg, 0.074 mmol) and CsF (225 mg, 1.48 mmol). The resulting mixture was stirred for 2 h at 80° C. under nitrogen atmosphere. The reaction solution was diluted with water, extracted with EtOAc (10 mL×3). The organic layer was washed with water and brine, dried over anhydrous Na2SO4 which was evaporated to dryness. The residue was purified by a silica gel column, eluted with PE/EtOAc=1:1 to afford the product. (180 mg, 73.8%). m/z [M+H]+=330.2.
(E)-3-(4-(2-ethoxyvinyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (180 mg, 0.55 mmol) was dissolved in HCOOH (2 mL). The resulting solution was stirred for 2 h at room temperature. The reaction solution was evaporated to dryness to afford product (125 mg, 75.3%) which was used directly in the next step. m/z [M+H]+=302.1.
The titled compound was synthesized in a manner similar to that in Example 147 Step 14 from 1-(6-((5-bromo-2-((5-ethyl-2-methoxy-4-(4-(piperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-2-methylquinolin-5-yl)phospholane 1-oxide and 2-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)acetaldehyde. 1H NMR (500 MHz, DMSO) δ 11.02 (s, 1H), 10.60 (s, 1H), 8.58 (d, J=8.0 Hz, 11H), 8.16-8.24 (m, 11H), 7.97 (s, 1H), 7.89 (d, J=9.1 Hz, 11H), 7.80 (s, 11H), 7.42 (d, J=8.9 Hz, 1H), 7.29 (s, 1H), 6.94-6.78 (m, 3H), 6.63 (s, 1H), 5.30 (dd, J=12.7, 5.4 Hz, 1H), 3.69 (s, 3H), 3.51 (s, 3H), 2.94-3.04 (m, 3H), 2.80-2.85 (m, 4H), 2.45-2.70 (m, 15H), 1.82-2.31 (m, 12H), 1.74-1.76 (m, 2H), 1.41-1.47 (m, 2H), 0.54 (s, 3H). [M+H]+=1018.4.
To a solution of 6-bromobenzo[d]oxazol-2(3H)-one (30.0 g, 140 mmol), 2,6-bis(benzyloxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (61 g, 147 mml), and Cu(OAc)2 (25.5 g, 140 mmol) in dry 1,4-dioxane (500 ml), were added pyridine (33.3 mL, 420 mmol), and activated 4 Å molecular sieve (20 g).
The mixture was stirred at 80° C. under the atmosphere of oxygen for 48 hours. After being cooled to rt, the mixture was diluted with ethyl acetate (1500 mL), and filtered through a pad of celite. The filtrate was washed with water (500 mL), and brine (3×500 mL), then dried over anhydrous sodium sulfate, concentrated under reduced pressure. The residue was purified by silica column chromatography (PE/DCM, 30%-50%) to afford crude product, which is further purified by trituration with PE to afford the target product (25.3 g, 35.8%). [M+H]+=503.1.
A 500 mL three-neck round-bottomed flask equipped with a magnetic stirrer, were charged with 3-(2,6-bis(benzyloxy)pyridin-3-yl)-6-bromobenzo[d]oxazol-2(3H)-one (20 g, 39.7 mmol), ((2-bromoethoxy)methyl)benzene (15.4 g, 71.5 mmol). NiI2 (2.48 g, 7.94 mmol), picolinimidamide hydrochloride (1.23 g, 7.94 mmol). NaI (2.98 g, 19.8 mmol), and Mn (6.55 g, 119 mmol). The mixture was degassed under vacuum and purged with N2 for three times. Dry DMAc (300 mL) was added into the round-bottomed flask by a syringe, the mixture was degassed under vacuum and purged with N2 once more. A solution of TFA (0.89 mL, 11.9 mmol) in DMAc (5 mL) was added into the round-bottomed flask by a syringe. The resulting mixture was stirred at 100° C. till complete conversion (confirmed by LCMS, ˜5 hours). After being cooled to rt, the mixture was diluted with ethyl acetate (1.5 L), then filtered through a pad of celite. The filtrate was washed with brine (5×500 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica column chromatography (PE/EA, 10%-20%) to afford crude product (8.00 g, 36.1%). [M+H]+=559.4.
To a solution of 6-(2-(benzyloxy)ethyl)-3-(2,6-bis(benzyloxy)pyridin-3-yl)benzo[d]oxazol-2(3H)-one (8.00 g, 14.3 mmol) in THF/EtOH (200 mL/200 mL), was added Pd/C (10 wt %, 5.00 g). The mixture was degassed under reduced pressure and purged with H2 for five times, and stirred under H2 at 50° C. overnight. After being cooled to rt, the mixture was diluted with EtOH/DCM (200 ml/400 mL), and sonicated in an ultrasonic washer for 5 minutes, then filtered through a pad of celite. The filtrate was concentrated under reduced pressure. Precipitate was observed during evaporation, then it was collected by filtration, and dried under vacuum to afford the first part of product (2.50 g). The filtrate was concentrated under reduced pressure and purified by silica column chromatography (PE/EA=1:1) to afford the other part of target product (0.80 g). Totally 3.30 g product was obtained (79.7%). [M+H]+=291.2.
The titled compound was synthesized in a manner similar to that in Example 147 Step 13 from 3-(6-(2-hydroxyethyl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione and IBX. [M+H]+=289.1.
The titled compound was synthesized in a manner similar to that in Example 147 Step 14 from 1-(6-((5-bromo-2-((5-ethyl-2-methoxy-4-(4-(piperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-2-methylquinolin-5-yl)phospholane 1-oxide and 2-(3-(2,6-dioxopiperidin-3-yl)-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)acetaldehyde. 1H NMR (500 MHz, DMSO) δ 11.14 (s, 1H), 10.60 (s, 1H), 8.57 (d, J=8.8 Hz, 1H), 8.15 (s, 1H), 7.98 (s, 1H), 7.89 (d, J=9.1 Hz, 1H), 7.80 (s, 1H), 7.42 (d, J=8.9 Hz, 1H), 7.29 (s, 1H), 7.22 (s, 1H), 7.09 (d, J=8.1 Hz, 1H), 7.00 (d, J=8.1 Hz, 1H), 6.62 (s, 1H), 5.28 (dd, J=12.9, 5.2 Hz, 1H), 3.68 (s, 3H), 2.74-2.89 (m, 3H), 2.47-2.72 (m, 13H), 2.30-2.42 (m, 5H), 1.87-2.17 (m, 13H), 1.72-1.74 (m, 2H), 1.40-1.46 (m, 2H), 0.54 (s, 3H). [M+H]+=1005.4.
Into a 100-mL round-bottom flask, (2,6-dibromophenyl)acetic acid (0.85 g, 2.892 mmol). DMF (35 mL), 2,6-bis(benzyloxy)pyridin-3-amine hydrochloride (1.0 g, 2.916 mmol), DIEA (2.0 mL, 11.654 mmol) and HATU (1.3 g, 3.499 mmol) were added. The resulting solution was stirred overnight at room temperature. The resulting solution was diluted with H2O The solids were collected by filtration. The solid was washed with MeOH to afford 1.5 g (89.08%) product which was used in next step without further purification. [M+H]+=581.1.
Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was added N-[2,6-bis(benzyloxy)pyridin-3-yl]-2-(2,6-dibromophenyl) acetamide (580 mg, 0.996 mmol), NMP (15 mL). K2CO3 (688 mg, 4.978 mmol), acetylacetone (200 mg, 1.998 mmol) and CuCl (99 mg, 1.000 mmol). The resulting solution was stirred for 1.5 hr at 85° C. The reaction mixture was cooled to room temperature. The resulting solution was diluted with EtOAc. The resulting solution was extracted with brine and the organic layers combined and dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with DCM/EA (6:1) to afford 403 mg (80.1%) of desired product. [M+H]+=501.2.
Into a 50-mL round-bottom flask, was added 1-[2,6-bis(benzyloxy)pyridin-3-yl]-4-bromo-3H-indol-2-one (500 mg, 0.997 mmol). DMF (15 mL), NaH (189 mg, 5.0 mol). The resulting solution was stirred for 0.5 hr at room temperature. And then CH3I (850 mg, 5.988 mmol) was added to the mixture at room temperature. The reaction was stirred overnight at room temperature. The resulting solution was diluted with EA. The pH value of the solution was adjusted to <7 with 2N HCl. The resulting mixture was extracted with ethyl acetate and the organic layers combined. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The residue was applied onto a silica gel column with DCM/PE (3:1) to afford 401 mg (75%) of desired product. [M+H]+=529.2.
Into a 30-mL microwave vial #1 purged and maintained with an inert atmosphere of nitrogen, was placed zinc powder (490 mg, 7.555 mmol), THF (8 mL), TMSCI (41 mg, 0.377 mmol). The resulting solution was stirred for 10 min at room temperature. And then ethyl bromoacetate (630 mg, 3.778 mmol) was added to the mixture. The resulting solution was stirred for 1.5 hrs at 60° C. Into a 100-mL 3-necked round-bottom flask, purged and maintained with an inert atmosphere of nitrogen, was placed 1-[2,6-bis(benzyloxy)pyridin-3-yl]-4-bromo-3,3-dimethylindol-2-one (1 g, 1.889 mmol), THF (17 mL), Xphos (180 mg, 0.378 mmol), Pd2(dba)3 (170 mg, 0.189 mmol). To the above mixture was added the solution in vial #1 by a syringe through a millipore filter. The resulting solution was allowed to react for an additional 3 hrs at 60° C. The resulting solution was diluted with EtOAc. The pH value of the solution was adjusted to <7 with 2N HCl. The resulting solution was extracted with ethyl acetate and the organic layers combined and dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with EA/PE (1:2) to afford 810 mg (78.9%) of desired product. [M+H]+=537.2.
Into a 50-mL round-bottom flask, was placed ethyl 2-[1-[2,6-bis(benzyloxy)pyridine-3-yl]-3,3-dimethyl-2-oxoindol-4-yl]acetate (740 mg, 1.379 mmol), THF (10 mL), H2O (1 mL), NaOH (276 mg, 6.901 mmol). The resulting solution was stirred for 3 hr at 65° C. The pH value of the solution was adjusted to <7 with 2N HCl (1 mL). The resulting solution was extracted with ethyl acetate and the organic layers combined and concentrated under vacuum to afford 502 mg (71.29%) of desired product which was used in next step without further purification. [M+H]+=509.2.
Into a 50-mL round-bottom flask, was placed [1-[2,6-bis(benzyloxy)pyridin-3-yl]-3,3-dimethyl-2-oxoindol-4-yl] acetic acid (600 mg, 1.180 mmol), THF (15 mL). And then BH3 (1M in THF, 6 mL) was added dropwise to the mixture at room temperature. The resulting solution was stirred for 5 hr at room temperature. The reaction was then quenched by the addition of MeOH (10 mL). The resulting mixture was concentrated under vacuum to afford the crude residue which was purified with EA/PE (1:1) to afford 400 mg (68.5%) of desired product. [M+H]+=495.2.
Into a 100-mL round-bottom flask, was placed 1-[2,6-bis(benzyloxy)pyridin-3-yl]-4-(2-hydroxyethyl)-3,3-dimethylindol-2-one (400 mg, 0.809 mmol). EtOH (15 mL), THF (15 mL), AcOH (0.50 mL), Pd/C (400 mg, 10% wt) at hydrogen atmosphere. The resulting solution was stirred overnight at 50° C. and the solids were filtered out. The organic phase was concentrated under vacuum to afford 213 mg (83.37%) of desired product [M+H]+=317.1.
The titled compound was synthesized in a manner similar to that in Example 147 Step 13 from 3-[4-(2-hydroxyethyl)-3,3-dimethyl-2-oxoindol-1-yl]piperidine-2,6-dione and IBX. [M+H]+=315.2.
The titled compound was synthesized in a manner similar to that in Example 147 Step 14 from 1-(6-((5-bromo-2-((5-ethyl-2-methoxy-4-(4-(piperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-2-methylquinolin-5-yl)phospholane 1-oxide and 2-(1-(2,6-dioxopiperidin-3-yl)-3,3-dimethyl-2-oxoindolin-4-yl)acetaldehyde. 1H NMR (500 MHz, DMSO) δ 11.07 (s, 1H), 10.68 (s, 1H), 8.64 (d, J=8.8 Hz, 1H), 8.29 (s, 1H), 8.23 (s, 1H), 8.04 (s, 1H), 7.96 (d, J=9.1 Hz, 1H), 7.87 (s, 1H), 7.49 (d, J=8.9 Hz, 1H), 7.36 (s, 1H), 7.17 (t, J=7.8 Hz, 1H), 6.91 (d, J=7.8 Hz, 1H), 6.83 (s, 1H), 6.69 (s, 1H), 5.21 (s, 1H), 3.75 (s, 3H), 2.75-2.94 (m, 6H), 2.51-2.74 (m, 14H), 1.89-2.32 (m, 13H), 1.81 (d, J=10.9 Hz, 2H), 1.51 (dd, J=20.3, 11.3 Hz, 2H), 1.38 (d, J=4.1 Hz, 6H), 0.61 (s, 3H). [M+H]+=1031.4.
The titled compound was synthesized in a manner similar to that in Example 147 Step 14 from 1-(6-((5-bromo-2-((5-ethyl-2-methoxy-4-(4-(piperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-2-methylquinolin-5-yl)phospholane 1-oxide and 3-(2,6-difluoro-4-(2-hydroxyethyl)phenyl)piperidine-2,6-dione.
1H NMR (500 MHz, DMSO) δ 10.95 (s, 1H), 10.67 (s, 1H), 8.64 (d, J=8.7 Hz, 1H), 8.24 (d, J=11.0 Hz, 1H), 8.04 (s, 1H), 7.96 (d, J=9.1 Hz, 1H), 7.87 (s, 1H), 7.49 (d, J=8.9 Hz, 1H), 7.36 (s, 1H), 7.02 (d, J=10.1 Hz, 2H), 6.69 (s, 1H), 4.20 (dd, J=12.6, 5.0 Hz, 1H), 3.75 (s, 3H), 2.51-2.92 (m, 16H), 2.36-2.48 (m, 4H), 1.88-2.30 (m, 14H), 1.80 (d, J=10.9 Hz, 2H), 1.50 (dd, J=20.2, 11.3 Hz, 2H), 0.61 (s, 3H). [M+H]+=984.3.
The titled compound was synthesized in a procedure similar to Example 77.
1H NMR (500 MHz, DMSO) δ 10.86 (s, 1H), 10.67 (s, 1H), 8.65 (s, 1H), 8.22 (s, 1H), 8.04 (s, 1H), 7.96 (d, J=9.0 Hz, 1H), 7.86 (s, 1H), 7.49 (d, J=8.9 Hz, 1H), 7.37 (s, 1H), 6.69 (s, 1H), 6.17 (d, J=11.1 Hz, 2H), 4.03 (t, J=7.4 Hz, 3H), 3.91 (t, J=6.1 Hz, 2H), 3.79-3.86 (m, 1H), 3.75 (s, 3H), 3.48 (s, 2H), 2.87-2.89 (m, 2H), 2.72-2.82 (m, 1H), 2.56-2.71 (m, 5H), 2.51-2.54 (m, 4H), 2.45-2.49 (m, 3H), 2.31-2.39 (m, 1H), 2.17-2.26 (m, 2H), 1.87-2.16 (m, 10H), 1.79 (d, J=10.8 Hz, 2H), 1.53 (dd, J=20.4, 11.3 Hz, 2H), 0.61 (s, 3H). [M+H]+=1039.4.
The titled compound was synthesized in a manner similar to that in Example 77 Step 12 from 1-(2-(5-bromo-2-((5-ethyl-2-methoxy-4-(4-(piperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)phospholane 1-oxide and (3R)-1-(4-(2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)pyrrolidine-3-carboxylic acid. 1H NMR (500 MHz, DMSO) δ 10.78 (s, 1H), 10.50 (s, 11H), 8.19 (d, J=12.7 Hz, 11H), 8.12 (s, 11H), 7.99 (s, 11H), 7.29-7.39 (m, 3H), 7.10 (t, J=7.3 Hz, 11H), 6.69 (s, 1H), 6.16 (d, J=12.2 Hz, 2H), 3.95 (dd, J=12.5, 4.9 Hz, 1H), 3.69 (s, 3H), 3.37-3.49 (m, 7H), 3.16-3.27 (in, 6H), 2.93-2.95 (m, 2H), 2.47-2.76 (m, 5H), 2.19-2.36 (m, 2H), 1.78-2.13 (m, 14H), 1.50-1.56 (m, 2H), 0.94 (t, J=7.4 Hz, 3H). [M+H]+=988.3.
To a solution of 2-methylquinolin-6-amine (5.3 g, 33.5 mmol) in HOAc (60 mL) was added IC1 (6.5 g, 40.3 mmol) at 20° C. Then the mixture was stirred at 20° C. for 1 hr. The reaction solution was concentrated under vacuum. Then the mixture was adjusted to pH=8 with sat. aq. NaHCO3 solution and extracted with DCM (150 mL). The organic phase was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated in vacuum, 5-iodo-2-methylquinolin-6-amine (8 g, 83.7%) was obtained. [M+H]+=285.0.
To a solution of 5-iodo-2-methylquinolin-6-amine (4 g, 14 mmol) and diallylphosphine oxide (3.6 g, 28 mmol) in dioxane (80 mL) was added K3PO4 (7.4 g, 35 mmol), then Pd(OAc)2 (316 mg, 1.4 mmol) and Xantphos (813 mg, 1.4 mmol) were added to the mixture at 20° C. The suspension was degassed under vacuum and purged with N2 three times. Then the mixture was stirred at 100° C. for 15 hrs. The mixture was filtered and concentrated in vacuum. The residue was purified by column chromatography (DCM/MeOH=20/1 to 10/1) to afford diallyl(6-amino-2-methylquinolin-5-yl)phosphine oxide (2.1 g, 52.2%) as a brown solid. [M+H]+=287.1.
Step 3: N-(5-(diallylphosphoryl)-2-methylquinolin-6-yl)pivalamide
To a solution of diallyl(6-amino-2-methylquinolin-5-yl)phosphine oxide (2.1 g, 7.3 mmol) in DCM (50 mL) was added TEA (1.85 g, 18.3 mmol), then pivaloyl chloride (1.06 g, 8.8 mmol) was added dropwise in 5 min. The resulting solution was stirred at rt for 3 h. The reaction mixture was diluted with DCM, washed water and brine, dried over anhydrous Na2SO4. The organic phase was evaporated to dryness to afford N-(5-(diallylphosphoryl)-2-methylquinolin-6-yl)pivalamide. (2.6 g, 95.9%). [M+H]+=371.2.
To a solution of N-(5-(diallylphosphoryl)-2-methylquinolin-6-yl)pivalamide (2.6 g, 7.0 mmol) in DCM (200 mL) was added HOVEYDA-Grubbs catalyst (878 mg, 1.4 mmol). The reaction mixture was stirred for 16 h at room temperature. The mixture was concentrated in vacuum. The residue was purified by column chromatography (DCM/MeOH=20/1 to 10/1) to afford N-(2-methyl-5-(l-oxido-2,5-dihydrophosphol-1-yl)quinolin-6-yl)pivalamide (2 g, 83.3%) as a dark-brown solid. [M+H]+=343.2.
N-(2-methyl-5-(1-oxido-2,5-dihydrophosphol-1-yl)quinolin-6-yl)pivalamide (2 g, 5.8 mmol) was dissolved in dioxane (15 mL). HCl (2 M, 15 mL) was added to the reaction mixture. The resulting solution was stirred for 15 h at 100° C. The reaction solution was evaporated to dryness, the reside was dissolved in water, the pH value was adjusted to 8-9 with NaOH (1M), extracted with DCM, then the organic phase was concentrated under vacuum to afford 1-(6-amino-2-methylquinolin-5-yl)-2,5-dihydrophosphole 1-oxide (1.3 g, 86.1%) and used directly to the next step without further purification. [M+H]+=259.1.
To a solution of 1-(6-amino-2-methylquinolin-5-yl)-2,5-dihydrophosphole 1-oxide (500 mg, 1.9 mmol) in THF (15 mL) was added 5-bromo-2,4-dichloropyrimidine (1.1 g, 4.8 mmol) at 0° C. And then LiHMDS (1 M, 3.8 mL, 3.8 mmol) was added to the reaction mixture at 0° C. The mixture was stirred at 20° C. for 3 hrs. Water (10 mL) was poured into the mixture, which was further extracted with DCM (20 mL×3). The combined organic phase was washed with brine (20 mL), dried over Na2SO4, filtered and concentrated in vacuum. The residue was purified by column chromatography (DCM/MeOH=10/1 to 5/1) to afford 1-(6-((5-bromo-2-chloropyrimidin-4-yl)amino)-2-methylquinolin-5-yl)-2,5-dihydrophosphole 1-oxide (505 mg, 58.2%). [M+H]+=449.0.
To a solution of 1-(6-((5-bromo-2-chloropyrimidin-4-yl)amino)-2-methylquinolin-5-yl)-2,5-dihydrophosphole 1-oxide (505 mg, 1.1 mmol) in n-BuOH (20 mL) was added tert-butyl 4-(1-(4-amino-2-ethyl-5-methoxyphenyl)piperidin-4-yl)piperazine-1-carboxylate (472 mg, 1.1 mmol) at 20° C. 4-methylbenzenesulfonic acid (568 mg, 3.3 mmol) was added to the reaction mixture at 20° C. Then the mixture was stirred at 90° C. for 15 hrs. The reaction mixture was evaporated to dryness, water (20 mL) was poured into the mixture. Then the mixture was adjusted to pH=8 with sat. aq. NaHCO3 solution and extracted with DCM (20 mL×3). The organic phase was washed with brine (30 mL), dried over Na2SO4, filtered and concentrated in vacuum. The residue was purified by column chromatography (DCM/MeOH=10/1 to 5/1) to afford the product (485 mg, 58.9%). [M+H]+=731.3.
To a solution of 1-(6-((5-bromo-2-((5-ethyl-2-methoxy-4-(4-(piperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-2-methylquinolin-5-yl)-2,5-dihydrophosphole 1-oxide (50 mg, 0.07 mmol). (3R)-1-(4-(2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)pyrrolidine-3-carboxylic acid (35 mg, 0.1 mmol) and DIEA (26 mg, 0.2 mmol) in 10 mL DCM, 50% w.t. T3P in EtOAc solution (64 mg, 0.1 mmol) was added. The mixture was stirred at 25° C. for 16 hours. After LCMS showed the reaction was completed. The mixture was quenched with water (10 mL). The organic phase was concentrated in vacuum and purified by prep-HPLC with C-18 column chromatography (0.1% FA in water:acetonitrile=90:10˜50:50 gradient elution) to afford product (20.5 mg, 27.8% yield). 1H NMR (500 MHz, DMSO) δ 11.31 (s, 1H), 10.84 (s, 1H), 8.32 (s, 1H), 8.22 (s, 1H), 8.03 (s, 1H), 7.94 (dd, J=13.9, 9.3 Hz, 2H), 7.29-7.47 (m, 2H), 6.75 (s, 1H), 6.11-6.24 (m, 4H), 4.02 (dd, J=12.5, 4.9 Hz, 1H), 3.78 (s, 3H), 3.43-3.56 (m, 7H), 3.23-3.42 (m, 5H), 2.94-3.04 (m, 4H), 2.73-2.88 (m, 3H), 2.53-2.71 (m, 7H), 2.23-2.43 (m, 3H), 2.02-2.21 (m, 3H), 1.89-2.00 (m, 1H), 1.83 (d, J=10.4 Hz, 2H), 1.49-1.63 (m, 2H), 0.78 (s, 3H). [M+H]+=1051.4.
The titled compound was synthesized in a manner similar to that in Example 147 Step 14 from 1-(6-((5-bromo-2-((5-ethyl-2-methoxy-4-(4-(piperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-2-methylquinolin-5-yl)-2,5-dihydrophosphole 1-oxide and 3-(2,6-difluoro-4-(2-hydroxyethyl)phenyl)piperidine-2,6-dione. 1H NMR (500 MHz, DMSO) δ 11.25 (s, 1H), 10.88 (s, 1H), 8.24 (s, 1H), 8.15 (s, 1H), 7.96 (s, 1H), 7.79-7.91 (m, 2H), 7.18-7.43 (m, 2H), 6.95 (d, J=10.1 Hz, 2H), 6.67 (s, 1H), 6.07 (d, J=30.6 Hz, 2H), 4.13 (dd, J=12.6, 5.0 Hz, 1H), 3.69 (s, 3H), 2.85-2.97 (m, 4H), 2.67-2.74 (m, 5H), 2.45-2.63 (m, 10H), 2.21-2.30 (m, 9H), 1.99-2.13 (m, 1H), 1.92-1.94 (m, 1H), 1.76 (d, J=10.9 Hz, 2H), 1.47 (dd, J=20.4, 11.4 Hz, 2H), 0.71 (s, 3H). [M+H]+=982.3.
The titled compound was synthesized in a manner similar to that in Example 147 Step 14 from 1-(6-((5-bromo-2-((5-ethyl-2-methoxy-4-(4-(piperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-2-methylquinolin-5-yl)-2,5-dihydrophosphole 1-oxide and 2-(3-(2,6-dioxopiperidin-3-yl)-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)acetaldehyde. 1H NMR (500 MHz, DMSO) δ 11.19 (d, J=54.9 Hz, 2H), 8.25 (s, 1H), 8.15 (s, 1H), 7.96 (s, 1H), 7.86 (t, J=9.8 Hz, 2H), 7.31 (dd, J=44.2, 23.7 Hz, 3H), 7.09 (d, J=8.1 Hz, 11H), 7.00 (d, J=8.1 Hz, 11H), 6.67 (s, 1H), 6.07 (d, J=30.6 Hz, 2H), 5.28 (dd, J=12.9, 5.2 Hz, 1H), 3.69 (s, 3H), 2.44-3.02 (m, 23H), 2.21-2.30 (m, 6H), 2.2.01-2.09 (m, 1H), 1.75-1.77 (m, 2H), 1.43-1.50 (m, 2H), 0.71 (s, 3H). [M+H]+=1003.3.
The titled compound was synthesized in a procedure similar to Example 77. 1H NMR (500 MHz, DMSO) δ 11.24 (s, 1H), 10.79 (s, 1H), 8.25 (s, 1H), 8.16 (s, 1H), 7.96 (s, 1H), 7.87 (dd, J=13.0, 9.4 Hz, 2H), 7.40-7.25 (m, 2H), 6.68 (s, 1H), 6.09 (dd, J=20.9, 14.5 Hz, 4H), 3.97 (t, J=7.6 Hz, 3H), 3.85 (t, J=6.3 Hz, 2H), 3.65-3.79 (m, 4H), 3.42 (s, 2H), 2.86-2.97 (m, 4H), 2.67-2.77 (m, 3H), 2.57-2.62 (m, 5H), 2.43-2.45 (m, 7H), 2.13-2.36 (m, 3H), 2.00-2.04 (m, 11H), 1.83-1.93 (m, 1H), 1.74-1.76 (m, 2H), 1.47-1.53 (m, 2H), 0.71 (s, 3H). [M+H]+=1037.3.
To a solution of 1-(2-((5-bromo-2-((5-ethyl-2-methoxy-4-(4-(piperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)phospholane 1-oxide (50 mg, 0.07 mmol), 1-(4-(2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)azetidine-3-carboxylic acid (synthesized by the similar method of example 77)(33 mg, 0.1 mmol) and DIEA (26 mg, 0.2 mmol) in 10 mL DCM, 50% w.t. T3P in EtOAc solution (64 mg, 0.1 mmol) was added. The mixture was stirred at 25° C. for 16 hours. After LCMS showed the reaction was completed. The mixture was quenched with water (10 mL). The organic phase was concentrated in vacuum and purified by prep-HPLC with C-18 column chromatography (0.1% FA in water:acetonitrile=90:10-50:50 gradient elution) to afford product (13.9 mg, 19.3% yield). 1H NMR (500 MHz, DMSO) δ 10.84 (s 11H), 10.57 (s, 1H), 8.19 (s, 1H), 8.14 (s, 1H), 8.05 (s, 1H), 7.37-7.51 (m, 3H), 7.17 (t, J=7.3 Hz, 1H), 6.76 (s, 2H), 6.17 (d, J=11.1 Hz, 2H), 4.02-4.05 (m, 3H), 3.80-3.93 (m, 3H), 3.76 (s, 3H), 3.50 (s, 3H), 2.99-3.02 (m, 2H), 2.63-2.81 (m, 3H), 2.54-2.55 (m, 4H), 2.38-2.48 (m, 4H), 1.84-2.13 (m, 12H), 1.56-1.63 (m, 2H), 1.01 (t, J=7.4 Hz, 3H). [M+H]+=974.3.
Cell Degradation
Cell Treatment
1a). BaF3-LTC (L858R/T790M/C797S) cells are seeded at 100000 cells/well in cell culture medium [RPMI1640 (Gibco, phenol red free, Cat #11835-030), 10% heat-inactive FBS, 1% PS (Gibco, Cat #10378)] in Corning 96 well plate (Cat #3799).
1b). On day 1, H1975-clone #28 (Del19/T790M/C797S, homozygous) cells are seeded at 20000 cells/well and 30000 cells/well correspondingly in cell culture medium [RPMI1640 (Gibco, Cat #72400-047), 10% heat-inactive FBS, 1% PS (Gibco, Cat #10378)] in Corning 96 well plate (Cat #3599).
BaF3-LTC (L858R/T790M/C797S) cells are treated with compounds diluted in 0.2% DMSO cell culture medium and incubate for 16 h, 37° C., 5% CO2. H1975-#28 cells are treated with compounds diluted in 0.2% DMSO cell culture medium on day 2, incubate for 16 h, 37° C., 5% CO2, the final concentration of compounds in all assay is start with 10 uM, 4-fold dilution, total 8 doses were included.
HTRF Assay
After 16 h treatment, add HTRF lysis buffer to each well; seal the plate and incubate 1 hour at room temperature on a plate shaker. Once the cells are lysed, 16 μL of cell lysate are transferred to a PE 384-well HTRF detection plate: 4 μL of pre-mixed HTRF antibodies are added to each well; Cover the plate with a plate sealer, spin 1000 rpm for 1 min, Incubate overnight at room temperature; Read on BMG PheraStar with HTRF protocol (337 nm-665 nm-620 nm).
The inhibition (degradation) percentage of the compound was calculated by the following equation:
Inhibition percentage of Compound=100−100×(Signal−low control)/(High control−low control),
The IC50 (DC50) value of a compound can be obtained by fitting the following equation
Y=Bottom+(TOP−Bottom)/(1+((IC50/X){circumflex over ( )}hillslope))
Wherein, X and Y are known values, and IC50. Hillslope, Top and Bottom are the parameters obtained by fitting with software. Y is the inhibition percentage (calculated from the equation), X is the concentration of the compound; IC50 is the concentration of the compound when the 50% inhibition is reached. The smaller the IC50 value is, the stronger the inhibitory ability of the compound is. Vice versa, the higher the IC50 value is, the weaker the ability the inhibitory ability of the compound is; Hillslope represents the slope of the fitted curve, generally around 1*; Bottom represents the minimum value of the curve obtained by data fitting, which is generally 0%±20%. Top represents the maximum value of the curve obtained by data fitting, which is generally 100%±20%. The experimental data were fitted by calculating and analyzing with Dotmatics data analysis software.
The foregoing examples and description of certain embodiments should be taken as illustrating, rather than as limiting the present invention as defined by the claims. As will be readily appreciated, numerous variations and combinations of the features set forth above can be utilized without departing from the present invention as set forth in the claims. All such variations are intended to be included within the scope of the present invention. All references cited are incorporated herein by reference in their entireties.
It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art in any country.
| Number | Date | Country | Kind |
|---|---|---|---|
| PCTCN2021091589 | Apr 2021 | WO | international |
